CinCor Pharma
CinCor Pharma was a Cincinnati-based clinical-stage biopharmaceutical company that developed CIN-107 (baxdrostat), a first-in-class aldosterone synthase inhibitor for treatment-resistant hypertension, primary aldosteronism, and chronic kidney disease, before being acquired by AstraZeneca in February 2023.
- Company typePrivate
- Founded2018
- HeadquartersCincinnati, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What CinCor Pharma does
CinCor Pharma was a Cincinnati-based clinical-stage biopharmaceutical company founded in 2018 that developed CIN-107 (later named baxdrostat and marketed as Baxfendy), a first-in-class selective aldosterone synthase inhibitor designed to lower blood pressure by blocking the enzyme that synthesizes aldosterone. The asset targeted treatment-resistant hypertension, primary aldosteronism, and chronic kidney disease, addressing an estimated 23 million US patients whose blood pressure remained uncontrolled despite two or more existing medications and representing the first new therapeutic approach in this space in roughly two decades. Phase III trials demonstrated a 15.7 mmHg systolic reduction from baseline and a 9.8 mmHg placebo-adjusted improvement (p<0.001) at the 2 mg dose.
CinCor funded development through a $50 million Series A in 2019, a $143 million Series B in October 2021 led by General Atlantic, and an upsized ~$225 million public offering in August 2022, raising roughly $368 million in total equity before being acquired by AstraZeneca in February 2023 for $1.3-1.8 billion in upfront payments to obtain baxdrostat. The drug received FDA approval in May 2026 as Baxfendy and is being commercialized through AstraZeneca's global pharmaceutical distribution network, with peak-sales projections of $5-10 billion annually.
As of the acquisition date, CinCor operates as a wholly-owned subsidiary within AstraZeneca's cardiorenal portfolio. Its leadership team included Marc de Garidel (CEO), co-founders Catherine Pearce (COO) and Jon Isaacsohn (former CEO), and Mason W. Freeman (Executive VP of Clinical Operations). The company's product was positioned to compete in the resistant hypertension segment where no novel mechanism of action had emerged for two decades.
CinCor Pharma firmographics
Firmographics- Name
- CinCor Pharma
- Website
- https://cincor.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- CinCor Pharma was a Cincinnati-based clinical-stage biopharmaceutical company that developed CIN-107 (baxdrostat), a first-in-class aldosterone synthase inhibitor for treatment-resistant hypertension, primary aldosteronism, and chronic kidney disease, before being acquired by AstraZeneca in February 2023.
- Ownership category
- akta.pro rank
CinCor Pharma industry classification
Industry- Product category
- Cardiovascular Pharmaceuticals
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Preventive Cardiology & Lipidology (HLAKABAF)
Keywords
Where CinCor Pharma is headquartered
LocationHeadquarters
- HQ city
- Cincinnati
- HQ country
- United States
- HQ region
- North America
Markets served
CinCor Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Product Development and Commercialization: CinCor Pharma was a clinical-stage biopharmaceutical company developing CIN-107 for hypertension, primary aldosteronism, and chronic kidney disease. The company pursued drug development through clinical trials with the goal of obtaining regulatory approval for commercialization. The company was acquired by AstraZeneca in 2023 for $1.8 billion, enabling commercialization of the drug through AstraZeneca's global pharmaceutical distribution network.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
CinCor Pharma product offering
Product offeringCore offering
CinCor Pharma developed CIN-107 (baxdrostat), a first-in-class selective aldosterone synthase inhibitor as a once-daily oral tablet for treating resistant hypertension, primary aldosteronism, and chronic kidney disease. The drug inhibits the enzyme that synthesizes aldosterone, a hormone that raises blood pressure, addressing an unmet need for approximately 23 million US patients with uncontrolled hypertension despite being on two or more medications.
Product overview
CinCor Pharma was a biopharmaceutical company that developed CIN-107 (later named baxdrostat, marketed as Baxfendy), a first-in-class selective aldosterone synthase inhibitor. The company focused on developing treatments for hypertension, primary aldosteronism, and chronic kidney disease. CinCor Pharma was acquired by AstraZeneca in February 2023 for approximately $1.3-1.8 billion, after which the drug continued through clinical trials and received FDA approval in May 2026 as Baxfendy, representing the first new therapeutic approach for uncontrolled hypertension in two decades.
Differentiator
Problem solved
Functional benefit
Brands
- CIN-107: A selective aldosterone synthase inhibitor developed for treating hypertension, primary aldosteronism, and chronic kidney disease. After acquisition by AstraZeneca, the compound was renamed baxdrostat (marketed as Baxfendy).
Products and services
- Baxfendy (baxdrostat)
Quantifiable outcome
- 2mg dose reduced systolic blood pressure by 15.7 mmHg from baseline with 9.8 mmHg placebo-adjusted reduction (p<0.001) at week 12 in patients with uncontrolled or resistant hypertension
- +2 more outcomes
Companies that use CinCor Pharma
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles1 record
CinCor Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
CinCor Pharma partnerships and signals
Strategic signalScale indicators5 records
Recent moves7 records
Expansion highlights4 records
CinCor Pharma competitors and assessment
Company assessmentMarket position
Strengths1 record
Weaknesses4 records
Competitive moat3 records
Key risks3 records
Customer concentration
CinCor Pharma social profiles
Digital presenceCinCor Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
CinCor Pharma leadership team
Management profileNumber of profiles
CinCor Pharma funding detail
Funding detailFunding overview
Funding rounds3 records
Investors14 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CinCor Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CinCor Pharma
What does CinCor Pharma do?
CinCor Pharma developed CIN-107 (baxdrostat), a first-in-class selective aldosterone synthase inhibitor as a once-daily oral tablet for treating resistant hypertension, primary aldosteronism, and chronic kidney disease. The drug inhibits the enzyme that synthesizes aldosterone, a hormone that raises blood pressure, addressing an unmet need for approximately 23 million US patients with uncontrolled hypertension despite being on two or more medications.
Is CinCor Pharma a public or private company?
CinCor Pharma is a private company. It is classified as corporate owned and is currently acquired.
When was CinCor Pharma founded?
CinCor Pharma was founded in 2018. It employs 11 to 50 people.
Where is CinCor Pharma based?
CinCor Pharma is headquartered in Cincinnati, United States, in the North America region.
How does CinCor Pharma make money?
One revenue line is on record: pharmaceutical Product Development and Commercialization.
Does CinCor Pharma have an API?
No public API is recorded for CinCor Pharma.
What industry is CinCor Pharma in?
CinCor Pharma's product category is Cardiovascular Pharmaceuticals. Its primary akta.pro industry code is HLAKABAF, Preventive Cardiology & Lipidology. Its SIC code is 2834.